
IRVINE, Calif., Feb. 17, 2015 /PRNewswire/ -- NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the maker of age-defying aesthetic products for skin and hair rejuvenation developed from adult adipose stem cells and other biologically active ingredients, has launched a national product promotion on 'Extra', the Emmy® Award–winning entertainment news program. Visible in more than 98% of the country, 'Extra' airs on major market affiliates including the key NBC Television Owned-and-Operated Stations.
"NuGene is offering a giveaway of our NuCell Universal Serum to watchers of the 'Extra' television program and visitors to the 'Extra' website," explained Ali Kharazmi CEO of NuGene. "This show reaches millions of people every week, and our 30 second spot featuring VP of Sales, Dr. Fady Elias, has been well received. It is exciting to be getting the word out about our regenerative product lines. We believe that once people know about our products and how they rejuvenate skin and hair that NuGene will quickly become a respected household name. We also expect this promotion to drive new prospective customers to our growing network of doctors, aestheticians and other skin and hair care professionals."
The company will be giving away one of its premier products, NuCell Universal Serum, to more than 50 lucky 'Extra' audience attendees as well as to selected visitors of the 'Extra' website. NuCell Universal Serum is formulated to improve skin texture and thickness, reduce the signs of aging and restore the skin's natural luminosity and health. The product retails for $299.99. For those that couldn't attend the 'Extra' taping, entries can be submitted online until February 25, 2015 for a chance to receive one of five Universal Serum sets.
About NuGene International, Inc.
Nugene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments". The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has two patents pending covering 15 unique applications and inventions. NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.
Forward-Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.
Investor/ Media Relations:
Chris Rosgen
Capital Market Relations
(949)481-9739
Logo - http://photos.prnewswire.com/prnh/20150216/175723LOGO
SOURCE NuGene International, Inc.
Share this article